Sub-clinical infection as an effective protocol for obtaining anti-Leishmania chagasi amastigote antibodies of different animal species

Fróes, Adriana M.; Santos, Cláudia V. D. dos; Penha Filho, Manoel Leoncio da; Teixeira, Márcia Cristina Aquino; Silva, Tânia Maria Correia; Oliveira, Geraldo Gileno de Sá; dosSantos, Washington Luis Conrado; Pontes-de-Carvalho, Lain Carlos; Neves, Neuza Maria Alcântara.
Artículo en Inglés | ARCA | ID: arc-7662

Documentos relacionados

  1. A historical review of the role of cytokines involved in leishmaniasis.
  2. Genome Analysis of Triploid Hybrid Leishmania Parasite from the Neotropics.
  3. A standardized intraperitoneal Glucantime™ for experimental treatment of cutaneous leishmaniasis caused by Leishmania amazonensis in BALB/c mice.
  4. Cutaneous Manifestations of Human and Murine Leishmaniasis.
  5. Sub-clinical infection as an effective protocol for obtaining anti-Leishmania chagasi amastigote antibodies of different animal species.
  6. Characterization of <i>Leishmania</i> (<i>L.</i>) <i>amazonensis</i> oligopeptidase B and its role in macrophage infection.
  7. FVB/NJ strain as a mouse model for cutaneous leishmaniasis by Leishmania (L.) amazonensis.
  8. Enhanced production of pro-inflammatory cytokines and chemokines in Ethiopian cutaneous leishmaniasis upon exposure to Leishmania aethiopica.
  9. CCR5 promotes the migration of pathological CD8+ T cells to the leishmanial lesions.
  10. Identification of a Protective <i>Leishmania</i> Antigen Dihydrolipoyl Dehydrogenase and Its Responding CD4<sup>+</sup> T Cells at Clonal Level.